Thermo Fisher will add 2 new filling lines to global expansion plans with $130M Singapore plant

Thermo Fisher Scientific headquarters
Thermo Fisher Scientific spent roughly $270 million in 2019 to fund its global expansion plans. (Thermo Fisher Scientific)

With global expansion plans underway, New Jersey contract manufacturer Thermo Fisher Scientific has signed some big checks in recent years to support its ambitious aims. Now, the company is set to build a new sterile filling facility in Asia that will help boost its regional presence. 

Thermo Fisher Scientific will dole out $130 million for a new Singapore facility to house two sterile filling lines that will eventually churn out up to 30 million doses per month of drugs and vaccines, the CDMO said Wednesday.

The new plant will employ up to 300 workers and is set to go online in 2022, Thermo said. 

Upcoming Webinar

Lifecycle Management Strategies Targeted For Patient Populations with Swallowing Disorders

Hear from industry experts as they discuss life cycle management strategies for patients with swallowing disorders and the overall impact on patient perception. The webinar will include several panel speakers representing different perspectives and case study examples. Save your spot and register today!

The Singapore facility will hold one large-scale line dedicated to live-virus filling—the first of its kind in the country—and a second focused on general fill-finish work. The plant will also house cleanroom capacity, labs, warehousing and offices to support production.

The project received backing from the Singapore Economic Development Board as part of an effort to support the regional distribution of sterile medicines. 

RELATED: Thermo Fisher continues global expansion push with CSL Behring biologics plant lease

Thermo, one of the largest players in the pharmaceutical contract manufacturing space, has wheeled and dealed in recent years to expand its global footprint.

In May, the firm inked a long-term tie-up at CSL Behring's Lengnau, Switzerland, facility to boost its biologics manufacturing capacity.

As part of the agreement, Thermo will take on operations of CSL's "state-of-the-art" biologics facility once it comes online in mid-2021. In return, the company will streamline discovery and manufacturing for CSL's drug portfolio, including hemophilia B therapy Idelvion.

RELATED: Thermo Fisher invests to boost production of cell culture media

The Singapore down payment is one of its biggest transactions of 2020, and it followed a busy year for Thermo's global expansion plans.

In November, the company said it would invest nearly $24 million in its biologics site at Inchinnan, Scotland, to boost its ability to manufacture cell culture media. Thermo will complete the work in 2021, it said. The month before, Thermo said its 2019 capital expenditures would reach $270 million with investments in its fill-finish operations; distribution in Asia, South America and India; and a virtual reality training center in Greenville, North Carolina.

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.